Biotechnology
Compare Stocks
2 / 10Stock Comparison
MDXG vs OSUR
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
MDXG vs OSUR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Medical - Instruments & Supplies |
| Market Cap | $544M | $216M |
| Revenue (TTM) | $389M | $85M |
| Net Income (TTM) | $31M | $-53M |
| Gross Margin | 81.0% | 38.8% |
| Operating Margin | 10.2% | -58.6% |
| Forward P/E | 292.8x | — |
| Total Debt | $23M | $13M |
| Cash & Equiv. | $166M | $199K |
MDXG vs OSUR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| MiMedx Group, Inc. (MDXG) | 100 | 101.9 | +1.9% |
| OraSure Technologie… (OSUR) | 100 | 20.6 | -79.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MDXG vs OSUR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
MDXG carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.22
- Rev growth 20.0%, EPS growth 14.3%, 3Y rev CAGR 16.1%
- -48.4% 10Y total return vs OSUR's -54.8%
OSUR is the clearest fit if your priority is momentum.
- +7.1% vs MDXG's -44.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.0% revenue growth vs OSUR's -38.1% | |
| Quality / Margins | 7.9% margin vs OSUR's -61.9% | |
| Stability / Safety | Beta 1.22 vs OSUR's 1.45 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +7.1% vs MDXG's -44.6% | |
| Efficiency (ROA) | 9.7% ROA vs OSUR's -16.6%, ROIC 42.3% vs -20.0% |
MDXG vs OSUR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
MDXG vs OSUR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
MDXG leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MDXG is the larger business by revenue, generating $389M annually — 4.6x OSUR's $85M. MDXG is the more profitable business, keeping 7.9% of every revenue dollar as net income compared to OSUR's -61.9%. On growth, MDXG holds the edge at -33.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $389M | $85M |
| EBITDAEarnings before interest/tax | $53M | -$45M |
| Net IncomeAfter-tax profit | $31M | -$53M |
| Free Cash FlowCash after capex | $66M | -$33M |
| Gross MarginGross profit ÷ Revenue | +81.0% | +38.8% |
| Operating MarginEBIT ÷ Revenue | +10.2% | -58.6% |
| Net MarginNet income ÷ Revenue | +7.9% | -61.9% |
| FCF MarginFCF ÷ Revenue | +17.0% | -38.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -33.1% | -99.9% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.4% | -52.4% |
Valuation Metrics
OSUR leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $544M | $216M |
| Enterprise ValueMkt cap + debt − cash | $400M | $229M |
| Trailing P/EPrice ÷ TTM EPS | 11.44x | -3.19x |
| Forward P/EPrice ÷ next-FY EPS est. | 292.80x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 5.08x | — |
| Price / SalesMarket cap ÷ Revenue | 1.30x | 1.88x |
| Price / BookPrice ÷ Book value/share | 2.14x | 0.65x |
| Price / FCFMarket cap ÷ FCF | 7.45x | — |
Profitability & Efficiency
MDXG leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
MDXG delivers a 12.9% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-19 for OSUR. OSUR carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to MDXG's 0.09x. On the Piotroski fundamental quality scale (0–9), MDXG scores 5/9 vs OSUR's 3/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +12.9% | -19.5% |
| ROA (TTM)Return on assets | +9.7% | -16.6% |
| ROICReturn on invested capital | +42.3% | -20.0% |
| ROCEReturn on capital employed | +25.7% | -16.8% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 3 |
| Debt / EquityFinancial leverage | 0.09x | 0.04x |
| Net DebtTotal debt minus cash | -$144M | $13M |
| Cash & Equiv.Liquid assets | $166M | $199,278 |
| Total DebtShort + long-term debt | $23M | $13M |
| Interest CoverageEBIT ÷ Interest expense | 25.32x | — |
Total Returns (Dividends Reinvested)
MDXG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MDXG five years ago would be worth $3,765 today (with dividends reinvested), compared to $3,083 for OSUR. Over the past 12 months, OSUR leads with a +7.1% total return vs MDXG's -44.6%. The 3-year compound annual growth rate (CAGR) favors MDXG at -14.3% vs OSUR's -24.6% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -43.5% | +26.1% |
| 1-Year ReturnPast 12 months | -44.6% | +7.1% |
| 3-Year ReturnCumulative with dividends | -37.1% | -57.1% |
| 5-Year ReturnCumulative with dividends | -62.3% | -69.2% |
| 10-Year ReturnCumulative with dividends | -48.4% | -54.8% |
| CAGR (3Y)Annualised 3-year return | -14.3% | -24.6% |
Risk & Volatility
Evenly matched — MDXG and OSUR each lead in 1 of 2 comparable metrics.
Risk & Volatility
MDXG is the less volatile stock with a 1.22 beta — it tends to amplify market swings less than OSUR's 1.45 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. OSUR currently trades 78.5% from its 52-week high vs MDXG's 45.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.22x | 1.45x |
| 52-Week HighHighest price in past year | $7.99 | $3.82 |
| 52-Week LowLowest price in past year | $3.02 | $2.08 |
| % of 52W HighCurrent price vs 52-week peak | +45.8% | +78.5% |
| RSI (14)Momentum oscillator 0–100 | 48.7 | 47.1 |
| Avg Volume (50D)Average daily shares traded | 1.4M | 455K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates MDXG as "Buy" and OSUR as "Hold". Consensus price targets imply 173.2% upside for MDXG (target: $10) vs 33.3% for OSUR (target: $4).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $10.00 | $4.00 |
| # AnalystsCovering analysts | 15 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 2 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.6% | +7.0% |
MDXG leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). OSUR leads in 1 (Valuation Metrics). 1 tied.
MDXG vs OSUR: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is MDXG or OSUR a better buy right now?
For growth investors, MiMedx Group, Inc.
(MDXG) is the stronger pick with 20. 0% revenue growth year-over-year, versus -38. 1% for OraSure Technologies, Inc. (OSUR). MiMedx Group, Inc. (MDXG) offers the better valuation at 11. 4x trailing P/E (292. 8x forward), making it the more compelling value choice. Analysts rate MiMedx Group, Inc. (MDXG) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MDXG or OSUR?
Over the past 5 years, MiMedx Group, Inc.
(MDXG) delivered a total return of -62. 3%, compared to -69. 2% for OraSure Technologies, Inc. (OSUR). Over 10 years, the gap is even starker: MDXG returned -48. 4% versus OSUR's -54. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MDXG or OSUR?
By beta (market sensitivity over 5 years), MiMedx Group, Inc.
(MDXG) is the lower-risk stock at 1. 22β versus OraSure Technologies, Inc. 's 1. 45β — meaning OSUR is approximately 19% more volatile than MDXG relative to the S&P 500. On balance sheet safety, OraSure Technologies, Inc. (OSUR) carries a lower debt/equity ratio of 4% versus 9% for MiMedx Group, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — MDXG or OSUR?
By revenue growth (latest reported year), MiMedx Group, Inc.
(MDXG) is pulling ahead at 20. 0% versus -38. 1% for OraSure Technologies, Inc. (OSUR). On earnings-per-share growth, the picture is similar: MiMedx Group, Inc. grew EPS 14. 3% year-over-year, compared to -261. 5% for OraSure Technologies, Inc.. Over a 3-year CAGR, MDXG leads at 16. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MDXG or OSUR?
MiMedx Group, Inc.
(MDXG) is the more profitable company, earning 11. 6% net margin versus -59. 8% for OraSure Technologies, Inc. — meaning it keeps 11. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MDXG leads at 15. 3% versus -59. 2% for OSUR. At the gross margin level — before operating expenses — MDXG leads at 82. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is MDXG or OSUR more undervalued right now?
Analyst consensus price targets imply the most upside for MDXG: 173.
2% to $10. 00.
07Which pays a better dividend — MDXG or OSUR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is MDXG or OSUR better for a retirement portfolio?
For long-horizon retirement investors, MiMedx Group, Inc.
(MDXG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 22)). Both have compounded well over 10 years (MDXG: -48. 4%, OSUR: -54. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between MDXG and OSUR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MDXG is a small-cap high-growth stock; OSUR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.